Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 9NSCLC 3Brain Neoplasms 3Neoplasms 2Squamous Cell Carcinoma of Lung 1Non-squamous Non-small Cell Lung Cancer 1Non-small Cell Lung Cancer Metastatic 1Non-Small-Cell Lung 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasms, Second Primary 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Bronchial Neoplasms 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 104Radiotherapy, Intensity-Modulated 59Gemcitabine 53toripalimab 35Fluorouracil 30Docetaxel 30Capecitabine 28Radiotherapy 23Drug Therapy 20camrelizumab 19nimotuzumab 16nedaplatin 12Chemoradiotherapy 12sintilimab 11apatinib 11Induction Chemotherapy 11Immune Checkpoint Inhibitors 11spartalizumab 10endostar protein 8Paclitaxel 8Cetuximab 8tislelizumab 7pembrolizumab 7Endostatins 7Bevacizumab 7anlotinib 6Radiation 6Endoscopy 6fludarabine 5S 1 (combination) 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Nasopharyngeal Carcinoma × icotinib × Clear all
NCT01534585 2018-04-17

Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma

Taizhou Hospital

Phase 1/2 Completed
48 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡